Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4420849 | 0.91 | GRM5 (0.55) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL4420852 | 0.91 | GRM5 (0.55) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL3697057 | 0.87 | LMNA (0.51) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL23343604 | 0.83 | GRM5 (0.51) | GRM5CYP1A2CYP3A4CACNA1CSCN5A | |
| SCHEMBL16099259 | 0.83 | GRM5 (0.50) | GRM5CYP1A2CYP3A4MAPTALDH1A1 | |
| SCHEMBL14808636 | 0.82 | GRM5 (0.43) | GRM5CYP1A2CYP3A4MAPTGAA | |
| SCHEMBL99227 | 0.79 | GRM5 (0.53) | GRM5CYP1A2MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL23276709 | 0.79 | GRM5 (0.60) | GRM5CYP1A2CYP3A4MAPTGAA | |
| SCHEMBL9256295 | 0.77 | GRM5 (0.48) | GRM5CYP1A2CYP3A4TSHRMAPT | |
| SCHEMBL6428985 | 0.77 | TSHR (0.47) | GRM5CYP1A2CYP3A4TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547705-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-04-03 | — | — | US | disclosed |
| US-7294631-B2 | Substituted 8′-pyri(MI)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| EP-1699795-B1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | EP | disclosed |
| EP-1557417-B1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives | SANOFI AVENTIS (FR) | 2007-03-07 | — | — | EP | disclosed |
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2007-01-11 | — | — | US | disclosed |
| EP-1699795-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKLYMINE]-PYRIMIDO[1,2A]PYRIMIDIN-6-ONE DERIVATIVES | Sanofi-Aventis (FR) | 2006-09-13 | — | — | EP | disclosed |
| EP-1557417-A1 | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2a] pyrimidin-6-one derivatives | Sanofi-Aventis (FR) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005058908-A1 | SUBSTITUTED 8’-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010539-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | GRM5 525/4885CYP1A2 2136/4885CYP3A4 4202/4885 |
| US-20080081820-A1 | SUBSTITUTED 8'-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | GRM5 768/4885CYP1A2 1683/4885CYP3A4 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.